Bharat Immunologicals & Biologicals Corporation Limited Stock price

Equities

BIBCL6

INE994B01014

Pharmaceuticals

Market Closed - Bombay S.E. 06:10:03 2024-03-28 am EDT 5-day change 1st Jan Change
28.28 INR -1.46% Intraday chart for Bharat Immunologicals & Biologicals Corporation Limited +3.82% -20.00%
Sales 2022 784M 9.41M Sales 2023 446M 5.35M Capitalization 958M 11.5M
Net income 2022 -87M -1.04M Net income 2023 -166M -1.99M EV / Sales 2022 2.48 x
Net Debt 2022 732M 8.79M Net Debt 2023 689M 8.27M EV / Sales 2023 3.69 x
P/E ratio 2022
-13.8 x
P/E ratio 2023
-5.76 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 40.75%
More Fundamentals * Assessed data
Dynamic Chart
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
EU countries agree to admit travellers vaccinated with WHO-approved shots RE
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Third Quarter Ended December 31, 2021 CI
EU proposes booster jabs for 2022 travel, opens to WHO vaccines RE
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter Ended September 30, 2021 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Full Year Ended March 31, 2021 CI
Bharat Immunologicals & Biologicals : to Receive Indian Government Funding for COVID Vaccine Production MT
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020 CI
More news
1 day-1.46%
1 week+3.82%
Current month-15.25%
1 month-10.70%
3 months-21.75%
6 months+17.69%
Current year-20.00%
More quotes
1 week
27.60
Extreme 27.6
31.26
1 month
26.60
Extreme 26.6
34.40
Current year
26.60
Extreme 26.6
42.00
1 year
20.50
Extreme 20.5
43.89
3 years
20.50
Extreme 20.5
94.50
5 years
5.41
Extreme 5.41
94.50
10 years
5.41
Extreme 5.41
94.50
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-09-16
Director of Finance/CFO - -
Director of Finance/CFO - 07-09-02
Members of the board TitleAgeSince
Director/Board Member - 16-10-31
Chairman - 16-10-31
Director/Board Member - 16-10-31
More insiders
Date Price Change Volume
24-03-28 28.28 -1.46% 137,243
24-03-27 28.7 -5.25% 130,997
24-03-26 30.29 +6.58% 249,888
24-03-22 28.42 +4.33% 133,169
24-03-21 27.24 -1.09% 71,503

Delayed Quote Bombay S.E., March 28, 2024 at 06:10 am EDT

More quotes
Bharat Immunologicals and Biologicals Corporation Limited is an India-based biotechnology company. The Company is primarily engaged in the manufacture of oral polio vaccine, zinc tablet, and diarrhea management kit. It operates under various segment, namely oral polio vaccine, zinc tablets, BIB VIT, and BIBSANIT. It is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The Company is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). It is also diversified into plasma-derived medicines and Oral Cholera vaccines. The Company's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.
More about the company
  1. Stock
  2. Equities
  3. Stock Bharat Immunologicals & Biologicals Corporation Limited - Bombay S.E.